Objectif
Over the past two decades, the pharmaceutical industry has witnessed an exponential growth in approved covalent drugs. The majority of such drugs incorporate a chemical warhead, a mild electrophilic reactive functional group that forms covalent bonds in a reversible or irreversible manner with nucleophilic aminoacid residues. The aim of this proposal is to assess the viability of a new chemical warhead in the discovery of novel kinase inhibitors.
Mots‑clés
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régime de financement
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsInstitution d’accueil
FUNDACIO PRIVADA INSTITUT CATALA D'INVESTIGACIO QUIMICA
Contribution nette de l'UE
€ 150 000,00
Adresse
AVENIDA PAISSOS CATALANS 16
43007 Tarragona
Espagne
43007 Tarragona
Espagne
Région
Este
Cataluña
Tarragona
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée